Back to School: How biopharma can reboot drug development. Access exclusive analysis here

ISIS 301012 subcutaneous mipomersen sodium: Additional Phase II data

Additional data from 16 patients enrolled in an open-label extension of

Read the full 116 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE